Coegin Pharma (COEGIN) Status Update summary

Recent developments and partnerships

• Agreement with the University of Bradford to commercialize pigmentation peptides, focusing on a skin-pigmentation peptide.

• Development agreements launched with a cosmetic company for skin pigmentation and with Scandinavian Biolabs for a hair-growth product.

Follicopeptide product overview and clinical results

• Follicopeptide, derived from human osteopontin, is designed for daily topical scalp application.

• Clinical studies report benefits in over 70% of users; safety and efficacy demonstrated in over 350 patients, for both men and women.

Commercialization and launch plans

• First hair-growth product series planned for 2025; targeting a Q4 2025 launch in Europe and the U.S., with production starting Q1 and finished product delivery by end of Q3.

• Business dialogues with potential partners validated the innovation and market demand; focus on experienced partners and scaling production for key markets.

• Plans to launch Follicopeptide as an ingredient in multiple products globally.